PMI
Picard Medical, Inc. AMEX Listed Aug 22, 2025$0.17
-1.43%
vs $0.17
Mkt Cap $268.2M
52w Low $0.11
0.5% of range
52w High $13.68
50d MA $0.37
200d MA $2.75
P/E (TTM)
—
EV/EBITDA
—
P/B
3.4x
Debt/Equity
1.8x
ROE
-712.6%
P/FCF
-0.8x
RSI (14)
38.20
ATR (14)
$0.05
Beta
4.56
50d MA
$0.37
200d MA
$2.75
Avg Volume
56.9M
Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the USA, Europe, and internationally. The company was incorporated in 2021 and is based in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc
1992 E. SILVERLAKE RD. · TUCSON, AZ 85713 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | — | -0.06 | — | 1.02 | -2.0% | -1.0% | -8.8% | +17.3% | -3.7% | +1.0% | — |
| Nov 14, 2025 | AMC | — | -0.19 | — | 2.70 | -0.7% | -3.7% | -2.3% | -6.7% | -7.2% | +3.2% | — |
| Sep 11, 2025 | AMC | — | -0.85 | — | 7.00 | +1.6% | +2.1% | +6.3% | +0.0% | -0.3% | -5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18 | H.C. Wainwright | Initiates | Neutral | — | $0.16 | $0.16 | +2.7% | +7.1% | -6.7% | -3.7% | -8.4% | +7.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Picard Medical, Inc. -- 8-K 5.02: Executive Change
Jun 24
8-K · 5.02
!!! Very High
Picard Medical, Inc. -- 8-K 5.02: Executive Change
Picard Medical promoted its Chief Financial Officer Georgina Smith to Chief Accounting Officer effective June 1, 2026, signaling potential CFO succession planning and organizational restructuring.
Jun 2
8-K · 7.01
! Medium
Picard Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 29
8-K · 1.01
!! High
Picard Medical, Inc. -- 8-K 1.01: Material Agreement
May 11
8-K · 1.01
!! High
Picard Medical, Inc. -- 8-K 1.01: Material Agreement
Picard Medical issued warrants through an exchange agreement, potentially diluting shareholder equity and affecting the company's capital structure and future stock price.
May 5
8-K
Picard Medical, Inc. -- 8-K Filing
Picard Medical reported first-quarter 2026 revenue growth driven by increased U.S. demand and improved pricing, signaling strengthening market traction for its medical devices.
Apr 22
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
PMI secured a financing agreement with Quick Capital, LLC, likely indicating the company needed short-term capital, which could signal operational cash flow challenges or expansion costs that investors should monitor for dilution risks.
Apr 13
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
SynCardia's FDA-approved artificial heart products strengthen PMI's portfolio and revenue potential, validating its investment in life-critical medical devices with significant market opportunity.
Mar 27
8-K
Unknown — 8-K Filing
Picard Medical reported full-year 2025 revenue growth and expanding adoption of its SynCardia Total Artificial Heart, signaling increasing market penetration in a high-value medical device category with significant growth potential.
Mar 25
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
SynCardia's presentation of next-generation artificial heart preclinical data at a major cardiology conference signals progress toward commercializing an improved product that could expand its addressable market and strengthen competitive positioning.
Mar 20
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
SynCardia's successful 119-day artificial heart implant demonstrates product viability and clinical acceptance, potentially validating Picard Medical's market opportunity and supporting future revenue growth in the cardiac device sector.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Picard Medical's successful four-year artificial heart bridge demonstrates product durability and safety, potentially expanding addressable patient population and strengthening competitive positioning in the cardiac device market.
Mar 17
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis of this filing because the content provided is incomplete and appears to be corrupted or improperly formatted XBRL metadata rather than actual financial disclosure information. Please provide the actual 8-K filing details or summary.
Mar 16
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
PMI disclosed media coverage of SynCardia's Total Artificial Heart on FOX Business, signaling positive publicity that could drive awareness and potentially boost adoption among heart failure patients and investors.
Mar 13
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
I cannot provide a specific analysis since the filing content is incomplete—only headers and signature blocks are shown without the actual disclosure details from the press release.
Mar 13
8-K · 7.01
! Medium
Picard Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Picard Medical (PMI) executive Andre Simon will present three presentations at the Technology and Heart Failure Therapeutics 2026 conference in Boston, demonstrating the company's active engagement in industry discussions around cardiac innovation.
Mar 2
8-K · 7.01
! Medium
Picard Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Picard Medical disclosed information via press release under Regulation FD, providing investors with material non-public information while limiting legal liability for the disclosure's accuracy.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Eversource Wealth Advisors, Llc | 997 | $88K | New | Mar 2026 |
| 2 | Aqr Capital Management Llc | 55,262 | $57K | New | Mar 2026 |
| 3 | Morgan Stanley | 23,106 | $40K | Added | Dec 2025 |
| 4 | Vanguard Portfolio Management Llc | 30,208 | $31K | New | Mar 2026 |
| 5 | Wealth Management Partners, Llc | 28,116 | $29K | — | Mar 2026 |
| 6 | Northern Trust Corp | 17,927 | $19K | Added | Mar 2026 |
| 7 | Fmr Llc | 7,016 | $7K | Reduced | Mar 2026 |
| 8 | Cwm, Llc | 3,119 | $3K | New | Mar 2026 |
| 9 | Ubs Group Ag | 2,725 | $3K | Reduced | Mar 2026 |
| 10 | Wells Fargo & Company/mn | 2,440 | $3K | New | Mar 2026 |
| 11 | Bnp Paribas Financial Markets | 2,346 | $2K | Added | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 2,032 | $2K | Added | Mar 2026 |
| 13 | Barclays Plc | 2,091 | $2K | Reduced | Mar 2026 |
| 14 | Russell Investments Group, Ltd. | 1,068 | $1K | Added | Mar 2026 |
| 15 | Citigroup Inc | 256 | $448 | New | Dec 2025 |
| 16 | Essential Partners Llc | 204 | $212 | New | Mar 2026 |
| 17 | Sterling Capital Management Llc | 93 | $97 | Reduced | Mar 2026 |
| 18 | Ifp Advisors, Inc | 27 | $28 | New | Mar 2026 |
| 19 | Farther Finance Advisors, Llc | 12 | $13 | New | Mar 2026 |
| 20 | Arax Advisory Partners | 8 | $8 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 16
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | WisdomTree International SmallCap Dividend Fund | 603,978 | $344K | Mar 2026 |
| 2 | WisdomTree Europe SmallCap Dividend Fund | 188,592 | $108K | Mar 2026 |
| 3 | Schwab Small-Cap Index Fund | 16,130 | $28K | Jan 2026 |
| 4 | VANGUARD RUSSELL 2000 INDEX FUND | 24,299 | $26K | Feb 2026 |
| 5 | iShares Micro-Cap ETF | 12,412 | $13K | Mar 2026 |
| 6 | VANGUARD RUSSELL 2000 GROWTH INDEX FUND | 4,762 | $5K | Feb 2026 |
| 7 | Global X Russell 2000 ETF | 2,201 | $4K | Jan 2026 |
| 8 | Victory Extended Market Index Fund | 2,163 | $4K | Jan 2026 |
| 9 | SmallCap Growth Fund I | 199 | $348 | Jan 2026 |
| 10 | ProShares Ultra Russell2000 | 306 | $330 | Feb 2026 |
| 11 | ProShares UltraPro Russell2000 | 301 | $325 | Feb 2026 |
| 12 | ProShares Russell 2000 High Income ETF | 211 | $228 | Feb 2026 |
| 13 | SmallCap Value Fund II | 68 | $119 | Jan 2026 |
| 14 | ULTRA SMALL CAP PROFUND | 64 | $112 | Jan 2026 |
| 15 | SMALL-CAP PROFUND | 4 | $7 | Jan 2026 |
| 16 | ProShares Hedge Replication ETF | 5 | $5 | Feb 2026 |
Valuation
Market Cap
$268.2M
Enterprise Value
$5.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.39x
P/B
3.41x
P/S
2.36x
P/FCF
-0.84x
EV/EBITDA
—
Shares Out
75.2M
Financials (TTM)
Revenue
$5.5M
Net Income
-$29.9M
EBITDA
-$23.7M
Free Cash Flow
-$15.7M
Op Cash Flow
-$15.7M
EPS Basic
$-0.75
EPS Diluted
$-0.45
EPS Forward
—
Gross Margin
15.2%
Op Margin
-256.8%
Net Margin
—
Balance Sheet
Total Assets
$22.5M
Total Liab.
$18.8M
Total Equity
$3.8M
Cash
$7.5M
LT Debt
$0
Book Value/Sh
$0.05
Debt/Equity
1.84x
Current Ratio
1.11
Quick Ratio
0.72
Returns & Growth
ROE
-712.6%
ROA
-119.8%
ROIC
-118.9%
Rev Growth YoY
+12.5%
EPS Growth YoY
-12.1%
Price Returns
2W
-11.7%
1M
-67.6%
3M
-86.3%
6M
-93.1%
12M
-96.8%
Technicals
52W High
$13.68
52W Low
$0.11
50d MA
$0.37
200d MA
$2.75
RSI (14)
38.20
ATR (14)
$0.05
Beta
4.56
Avg Volume
56.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Dec 29, 2008
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 8:08pm
· Source: financialmodelingprep.com